Q1 2017 Neos Therapeutics Inc Earnings Call

9/5/2017 8:30

Conference Call Neos Therapeutics Inc

Neos Therapeutics Inc Conference call will be held on May 9, 2017. During the earnings conference call's session Neos Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Neos Therapeutics Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing our proprietary modified-release drug delivery technology platform, which we have already used to develop our one product and two product candidates for the treatment of attention deficit hyperactivity disorder, or ADHD. Our product candidates are extended-release, or XR, medications in patient-friendly, orally disintegrating tablets, or ODT, or liquid suspension dosage forms. We received approval from the U.S. Food and Drug Administration, or FDA, for Adzenys XR-ODT, our amphetamine XR-ODT, on January 27, 2016. We expect to resubmit a new drug application, or NDA, for Cotempla XR-ODT, our methylphenidate XR-ODT, in the fourth quarter of 2016, following the completion of a bioequivalence bridging study. In addition, we plan to submit an NDA for NT-0201, our amphetamine XR liquid suspension, in the fourth quarter of 2016.    
Read more Conference Call

Neos Therapeutics Inc (NEOS)

2940 North Highway 360, Grand Prairie Texas 75050, United States